Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized, double-blind trial of sotatercept added to standard of care in pulmonary arterial hypertension
2017-004738-27Phase 2Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Aug 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Sotatercept + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary efficacy and safety endpoints during placebo-controlled treatment period. Started Aug 2018; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2017-004738-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004738-27.